Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5949918 | 0.89 | NQO1 (0.43) | TDP1TSHRSMN1; SMN2L3MBTL1CYP3A4 | |
| SCHEMBL661780 | 0.83 | TDP1 (0.58) | TDP1TSHRRAB9ANPC1MAPT | |
| SCHEMBL2560729 | 0.83 | TDP1 (0.58) | TDP1TSHRRAB9ANPC1MAPT | |
| SCHEMBL12527284 | 0.81 | WDR5 (0.47) | TSHRNPC1MAPTHPGDMAOB | |
| SCHEMBL22445082 | 0.81 | TDP1 (0.56) | TDP1TSHRRAB9ANPC1MAPT | |
| SCHEMBL777299 | 0.81 | TDP1 (0.56) | TDP1TSHRRAB9ANPC1MAPT | |
| SCHEMBL27037700 | 0.81 | LTA4H (0.50) | APP | |
| Hydrochloric Acid SCHEMBL8639741 | 0.81 | TDP1 (0.56) | TDP1TSHRRAB9ANPC1MAPT | |
| SCHEMBL13723134 | 0.80 | TDP1 (0.50) | TDP1TSHRRAB9ANPC1MAPT | |
| SCHEMBL13450837 | 0.80 | RXRA (0.45) | RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617799-B2 | Pyrazolopyrimidinone compounds | Orphagen Pharmaceuticals, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20240208982-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. | 2024-06-27 | — | — | US | disclosed |
| EP-4313988-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117396480-A | Pyrazolopyrimidinone compounds | 奥弗恩制药公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022204481-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204481-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-01 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-20110144060-A1 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-20110144060-A1 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-20110003759-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-06 | — | — | US | disclosed |
| US-20110003759-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-06 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090011994-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-08 | — | — | US | disclosed |
| US-20090011994-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | TDP1 2415/4885TSHR 2837/4885RAB9A 580/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TDP1 2415/4885TSHR 2837/4885RAB9A 580/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | TDP1 700/4885TSHR 3159/4885RAB9A 2430/4885 |
| US-20110144060-A1 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | MCHR1, MC1R, MCHR2 | TDP1 1686/4885TSHR 24/4885RAB9A 979/4885 |
| US-20240208982-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | CYP2C19, CYP3A4, CYP2C9 | TDP1 2042/4885TSHR 3807/4885RAB9A 605/4885 |
| US-20110003759-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | MCHR1, MCHR2, MC1R | TDP1 1503/4885TSHR 28/4885RAB9A 650/4885 |
| US-12617799-B2 | Pyrazolopyrimidinone compounds | CYP2B6, CBR1, CYP2D6 | TDP1 3412/4885TSHR 215/4885RAB9A 131/4885 |
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | TDP1 1860/4885TSHR 1626/4885RAB9A 1099/4885 |
| US-20090011994-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | MCHR1, MCHR2, MC1R | TDP1 1503/4885TSHR 28/4885RAB9A 650/4885 |
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | TDP1 2168/4885TSHR 3896/4885RAB9A 1214/4885 |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | TDP1 2168/4885TSHR 3896/4885RAB9A 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.